Techno Venture Management
VC Fund
Boston, United States
Techno Venture Management is a venture capital and private equity firm focused on healthcare industry.
- Total investments:
- 99
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Techno Venture Management invests in
Stages Techno Venture Management invests in
Countries Techno Venture Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $4.7M–$22M
- Series B
- $5.2M–$44M
Investment Focus
Industry
- Biotechnology 36 (36%)
- Health Care 20 (20%)
- Pharmaceutical 19 (19%)
- Medical 16 (16%)
- Software 11 (11%)
Stage
- Funding Round 36 (36%)
- Series B 20 (20%)
- Series A 15 (15%)
- Series C 10 (10%)
- Seed 4 (4%)
Country
- United States 33 (33%)
- Germany 18 (18%)
- United Kingdom 5 (5%)
- Switzerland 2 (2%)
- France 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Josef Moosholzer
General Partner
|
General Partner | Total investments: 0 | Find email | |
|
Karl Erich Probst
Head of Business Software Group
|
Head of Business Software Group | Total investments: 0 | Find email | |
Michael Nowak
General Partner
|
General Partner | Total investments: 0 | Find email | |
Stephen J. Hoffman
Principal and Investment Manager
|
Principal and Investment Manager | Total investments: 18 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Helomics
|
Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both tissue-based live and fixed cellular basedanalysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer. | $43M / Nov 11, 2008 | |
Precision Therapeutics
|
Precision Therapeutics is a pharmaceutical research and development business that develops personalized cancer treatments for patients. | $20M / Series B / Feb 22, 2006 | |
Streaming21
|
Streaming21 is a solution provider of seamless on-demand and IP broadcasting service platform for connected digital home. | Aug 16, 2005 | |
Revolt Technology
|
ReVolt Technology is a technology company, which is developing a rechargeable zinc-air battery. ReVolt's batteries may enable more high-power consumer devices, electric vehicles and renewable energy storage. The technology is a result of six years of intense research and development at SINTEF (the largest independent research institute inScandinavia). Research on material combinations has solved issues historically related to the metal-air technology; power, lifetime and rechargeability. | $7.7M / Series A / Jun 28, 2005 | |
VPIsystems
|
VPIsystems (formerly VPI Virtual Photonics) develops and markets network planning software and services for the telecommunications industry in the United States and internationally. Its products include Photonic Design Automation, a solution for the modeling and optimization of photonic components and subsystems; and OnePlan, an integrated networkplanning system that enables communications service providers, systems integrators, and manufacturers to design, plan, and implement their transition to an IP-based network. The company serves wireline, wireless, and broadband carriers; and network equipment manufacturers and optical equipment vendors. VPIsystems, Inc. has strategic alliances with Accenture, HP, Logica, and Tech Mahindra. The company was founded as VPI Virtual Photonics, Inc. in 1997 and changed its name to VPIsystems, Inc. in July 2001. VPIsystems, Inc. is based in Holmdel, New Jersey with additional offices in Europe, Asia, and Australia. | $9M / Mar 01, 2005 | |
Genetix Biotherapeutics Inc.
|
bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaborationarrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates. | $12M / Oct 07, 2004 | |
iTAC Software
|
ITAC Software provides and develops manufacturing executing systems and solutions to the manufacturing industry. | $4.9M / Series C / Oct 06, 2004 | |
Coley Pharmaceutical Group
|
Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changedits name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc. | $25.2M / Series G / Sep 14, 2004 | |
Enanta Pharmaceuticals
|
Enanta Pharmaceuticals, Inc., a research and development company, engages in the discovery, development, and promotion of small molecule drugs in the areas of anti-infective.It develops protease, NS5A, polymerase, and cyclophilin-based inhibitors for the treatment of hepatitis C virus (HCV). The company also develops ABT-450/r, an oralprotease inhibitor for the treatment of hepatitis C (HCV) infection.In addition, it develops Bicyclolides, a macrolide antibiotic, which overcomes bacterial resistance; and EDP-420, a bicyclolide antibiotic for the treatment of community-acquired pneumonia.The company's antibacterial focus areas include superbugs, respiratory tract infections, and intravenous and oral treatments for hospital and community MRSA.The company has strategic alliances with Abbott Laboratories; and Shionogi & Co., LTD. Enanta Pharmaceuticals, Inc. was formerly known as NovirX, Inc. and changed its name to Enanta Pharmaceuticals, Inc. in May 1999.The company was founded in 1998 and is based in Watertown, Massachusetts. | $20M / Aug 31, 2004 | |
Infitel International
|
Infitel International develops and markets pioneering network-convergent technology. | $6.6M / Aug 16, 2004 | |
| See all 99 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Techno Venture Management invest in?
Techno Venture Management invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Funding Round and Series B stage. Most of the 99 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Techno Venture Management's check size?
Techno Venture Management typically joins rounds of $4.7M–$22M at Series A and $5.2M–$44M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Techno Venture Management participates in.
How do I contact Techno Venture Management?
Public channels for Techno Venture Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Techno Venture Management?
The team at Techno Venture Management includes Josef Moosholzer (General Partner), Karl Erich Probst (Head of Business Software Group) and Michael Nowak (General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
